75 related articles for article (PubMed ID: 31970085)
21. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
Zaanan A; Taieb J
Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
[TBL] [Abstract][Full Text] [Related]
22. Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature.
Gkekas I; Novotny J; Pecen L; Strigård K; Palmqvist R; Gunnarsson U
Anticancer Res; 2017 Dec; 37(12):6563-6574. PubMed ID: 29187431
[TBL] [Abstract][Full Text] [Related]
23. Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer.
Dai D; Zhao X; Li X; Shu Y; Shen B; Chen X; Chen D; Wang D
Front Oncol; 2019; 9():1452. PubMed ID: 31970085
[No Abstract] [Full Text] [Related]
24. Survival impact of microsatellite instability in stage II gastric cancer patients who received S-1 adjuvant monotherapy after curative resection.
Sato C; Kawakami H; Tanaka R; Satake H; Inoue K; Kimura Y; Fujita J; Kawabata R; Chiba Y; Satoh T; Nakagawa K
Sci Rep; 2023 Jul; 13(1):10826. PubMed ID: 37402831
[TBL] [Abstract][Full Text] [Related]
25. Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer.
Duan R; Li X; Zeng D; Chen X; Shen B; Zhu D; Zhu L; Yu Y; Wang D
Front Immunol; 2020; 11():609337. PubMed ID: 33569057
[TBL] [Abstract][Full Text] [Related]
26. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.
Roh CK; Choi YY; Choi S; Seo WJ; Cho M; Jang E; Son T; Kim HI; Kim H; Hyung WJ; Huh YM; Noh SH; Cheong JH
Yonsei Med J; 2019 Feb; 60(2):132-139. PubMed ID: 30666834
[TBL] [Abstract][Full Text] [Related]
27. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
28. Predicting the Efficacy of 5-Fluorouracil-Based Adjuvant Chemotherapy in Gastric Cancer by Microsatellite Instability: A Meta-Analysis.
Zhao F; Yuan X; Ren D; Shen G; Wang Z; Zheng F; Ahmad R; Ma Z; Zhao J
J Environ Pathol Toxicol Oncol; 2019; 38(1):21-28. PubMed ID: 30806287
[TBL] [Abstract][Full Text] [Related]
29. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P; Li L; Jiang X; Li Q
J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
[TBL] [Abstract][Full Text] [Related]
30. A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer.
Zhao X; Dai D; Li X; Shen B; Chen X; Shu Y; Wang D
Gastric Cancer; 2019 Nov; 22(6):1121-1129. PubMed ID: 30989434
[TBL] [Abstract][Full Text] [Related]
31. Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
Zeng D; Li M; Zhou R; Zhang J; Sun H; Shi M; Bin J; Liao Y; Rao J; Liao W
Cancer Immunol Res; 2019 May; 7(5):737-750. PubMed ID: 30842092
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant radiochemotherapy vs. chemotherapy alone in gastric cancer: a meta-analysis.
Matuschek C; Haussmann J; Bölke E; Tamaskovics B; Djiepmo Njanang FJ; Orth K; Peiper M; Gerber PA; Anooshar B; Kammers K; Budach W
Strahlenther Onkol; 2019 Aug; 195(8):695-706. PubMed ID: 30796495
[TBL] [Abstract][Full Text] [Related]
33. Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer": Are we There Yet?
Mondaca S; Yoon SS; Strong VE; Ku GY; Ilson DH; Greally M; Janjigian YY
Ann Surg; 2019 Aug; 270(2):e39-e40. PubMed ID: 30480560
[No Abstract] [Full Text] [Related]
34. Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis of the literature from the past 20 years.
Cai Z; Yin Y; Shen C; Wang J; Yin X; Chen Z; Zhou Y; Zhang B
Surg Oncol; 2018 Sep; 27(3):563-574. PubMed ID: 30217320
[TBL] [Abstract][Full Text] [Related]
35. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.
Cai Z; Yin Y; Yin Y; Shen C; Wang J; Yin X; Chen Z; Zhou Y; Zhang B
Gastric Cancer; 2018 Nov; 21(6):1031-1040. PubMed ID: 29728791
[TBL] [Abstract][Full Text] [Related]
37. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
[TBL] [Abstract][Full Text] [Related]
38. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project.
Sohn BH; Hwang JE; Jang HJ; Lee HS; Oh SC; Shim JJ; Lee KW; Kim EH; Yim SY; Lee SH; Cheong JH; Jeong W; Cho JY; Kim J; Chae J; Lee J; Kang WK; Kim S; Noh SH; Ajani JA; Lee JS
Clin Cancer Res; 2017 Aug; 23(15):4441-4449. PubMed ID: 28747339
[No Abstract] [Full Text] [Related]
39. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
Smyth EC; Wotherspoon A; Peckitt C; Gonzalez D; Hulkki-Wilson S; Eltahir Z; Fassan M; Rugge M; Valeri N; Okines A; Hewish M; Allum W; Stenning S; Nankivell M; Langley R; Cunningham D
JAMA Oncol; 2017 Sep; 3(9):1197-1203. PubMed ID: 28241187
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum RR; Liang H; Deng L; Fu YX
Nat Rev Clin Oncol; 2017 Jun; 14(6):365-379. PubMed ID: 28094262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
